Abstract
Acute myocardial infarction (AMI) is one of the leading causes of death worldwide. Despite recent advances in clinical management, reoccurence of heart failure after AMI remains high, in part because of the limited capacity of cardiac tissue to repair after AMI-induced cell death. Growth factor-based therapy has emerged as an alternative AMI treatment strategy. Understanding the underlying mechanisms of growth factor cardioprotective and regenerative actions is important. This review focuses on the function of different growth factors at each stage of the cardiac repair process. Recent evidence for growth factor therapy in preclinical and clinical trials is included. Finally, different delivery strategies are reviewed with a view to providing workable strategies for clinical translation.
summary
Acute myocardial infarction is a serious, life-threatening disease. Current treatments for acute myocardial infarction are unsatisfactory, and new treatments are required. Growth factors are promising treatments for myocardial infarction. It is intriguing to understand how growth factors provide cardioprotective benefits. This article describes the various growth factors used to treat myocardial infarction and how they are delivered to the infarcted heart.
Acknowledgments
X Cui would like to acknowledge the support of the Health Research Council of New Zealand (19/779); New Zealand Ministry of Business, Innovation and Employment (Ministry of Business, Innovation and Employment Science Whitinga Fellowship; MWF-UOO2103); Foundation Advice Limited (emerging researcher fellowship); and National Heart Foundation of New Zealand (1891, 1896).
Financial & competing interests disclosure
This study was funded by the National Natural Science Foundation of China (82170281,U2004203), Henan Thousand Talents Program (ZYQR201912131) and Excellent Youth Science Foundation of Henan Province (202300410362). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.